甲状腺结节实时灰阶超声造影的临床研究
|
摘要
目的
1.观察甲状腺结节实时灰阶超声造影的增强形式及时间-强度曲线特征,并与常规超声进行比较。
2.探讨超声造影对甲状腺良恶性结节的鉴别诊断价值。
资料和方法
对95例甲状腺结节患者共104个病灶进行超声造影研究。其中良性结节53个,恶性51个。超声造影剂为SonoVue,技术为低机械指数实时灰阶超声造影成像。
从5方面观察甲状腺结节超声造影增强特征,包括增强边界、增强形态、增强水平、增强方向和增强面积。将超声造影增强模式分为5种类型:无增强、均匀增强、不均匀增强、区域增强和环状增强。脱机分析动态图像在病灶不同部位及周围实质生成时间-强度曲线。总结不同病理类型甲状腺结节的造影增强特点和增强模式,比较甲状腺结节不同部位及良恶性结节之间的时间-强度曲线参数,比较超声造影和常规超声的诊断敏感性、特异性、阳性预测值、阴性预测值。
结果
1.增强边界不清提示恶性的敏感性47%,特异性87%,阳性预测值77%,阴性预测值63%。
2.增强形态不规则提示恶性的敏感性55%,特异性94%,阳性预测值90%,阴性预测值68%。
3.增强面积大于50%提示恶性的敏感性84%,特异性42%,阳性预测值58%,阴性预测值73%。
4.向心或离心性增强提示恶性的敏感性61%,特异性77%,阳性预测值72%,阴性预测值67%。
5.非均匀增强提示恶性的敏感性31%,特异性98%,阳性预测值94%,阴性预测值60%。
6.区域增强提示恶性的敏感性57%,特异性94%,阳性预测值91%,阴性预测值69%。
7.环状增强提示良性的敏感性83%,特异性94%,阳性预测值94%,阴性预测值83%。
8.多向+不规则廓清提示恶性的敏感性62%,特异性94%,阳性预测值94%,阴性预测值79%。
9.恶性结节较良性结节微泡进入强度低、上升时间短,且恶性结节周围实质增强上升速率大于良性结节。
10.超声造影结合灰阶及彩色多普勒诊断甲状腺结节的敏感性98.0%,特异性96.2%,高于常规超声。
结论
超声造影在甲状腺结节诊断和鉴别诊断中具有重要应用价值,超声造影结合灰阶及彩色多普勒的诊断敏感性、特异性均高于后两者单独应用或联合应用。
目的
探讨甲状腺结节实时灰阶超声造影增强形式及时间-强度曲线参数与CD34、CD105、VEGF、CK19和Ki67表达水平的关系。
资料和方法
采用低机械指数实时灰阶谐波超声造影技术,对62例甲状腺病人的62个结节进行超声造影,包括甲状腺乳头状癌30例,结甲27例,腺瘤4例,桥本病1例。术后石蜡标本行CD34、CD105、VEGF、CK19和K167免疫组织化学染色。比较甲状腺良恶性结节CD34、CD105、VEGF、CK19和K167表达水平,分析超声造影增强形式和时间-强度曲线各参数与CD34、CD105、VEGF、CK19和K167表达的关系。
结果
甲状腺乳头状癌结节的MVD和VEGF表达显著高于良性结节。恶性结节新生血管在肿瘤内分布不均衡,癌巢边缘MVD显著高于中心。标记肿瘤新生血管,CD105较CD34特异性更高。
CD34与甲状腺乳头状癌结节增强边界不清、形态不规则、向心+离心增强、区域增强呈正相关。CD105与恶性结节的增强形式之间未发现有意义的相关性。VEGF与结节增强边界不清、增强形态不规则、向心+离心增强正相关,与环状增强负相关。
CD34差值(边缘-中心)与边缘曲线上升速率和多向不规则廓清呈正相关。
VEGF与结节边缘、中心、周围实质的进入时间、达峰时间、上升时间呈负相关。与结节边缘、中心、周围实质的增强速率、多向不规则廓清呈正相关。
CK19与造影的增强方向、增强边界、增强形态、不均匀增强呈正相关;与均匀增强、环状增强呈负相关。
结论
1.甲状腺恶性结节的MVD和VEGF表达显著高于良性结节平均水平。
2.甲状腺实时灰阶超声造影可以反映甲状腺结节血管生成情况,甲状腺结节超声造增强形式及时间-强度曲线参数与MVD、VEGF和CK19之间的多项参数存在相关性。
PartⅠThe Research of Thyroid Nodules by Using Real-time Gray Contrast-enhanced Ultrasound Purpose
1.To observe the enhancement pattern and time-intensity curve of thyroid nodules by using contrast-enhanced ultrasound,and compare with conventional ultrasound.
2.To assess the value of contrast-enhanced ultrasound in differentiating thyroid benign and malignant nodule.
Material and methods
Ninety-five patients scheduled for surgical removal of the nodule were evaluated with real-time gray-scale contrast-enhanced ultrasound under a low mechanical index.The microbubble contrast agent was Sono Vue.Of the 104 lesions,53 lesions were benign,51 were malignant.
The enhancement of the thyroid nodules were characterized from five aspects, including margin,shape,level,orientation and the proportion of enhancement.There are five patterns of enhancement,including non,homogenous,heterogeneous, regional and rim-like enhancement.Analyzing the off-line dynamic images to create the Time-intensity curves in different parts of the thyroid nodules.To analyze the enhancement findings of thyroid nodules with repect to the histological results.To compare time-intensity curves of different parts of the nodule and between benign and malignant nodules.In addition,the sensitivity,specificity,PPV(positive predictive value),NPV(negative predictive value) of the contrast-enhancement ultrasound were calculated and compared with conventional ultrasound.
Results
1.Unclear enhancement-margin was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 47%/87%/77%/63%.
2.Irregular enhancement-shape was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 55%/94%/90%/68%.
3.Enhancement-proportion＞50%was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 84%/42%/58%/73%.
4.Centripetal and Centrifugal enhancement was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 61%/77%/72%/67%.
5.heterogeneous enhancement was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 31%/98%/94%/60%.
6.Region enhancement was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 57%/94%/91%/69%.
7.Rim-like enhancement was suggestive of benign with a sensitivity/specificity/PPV/NPV of 83%/94%/94%/83%.
8.Multiphase and irregular wash-out was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 62%/94%/94%/79%.
9.The baseline intensity signal was lower and the rising time was shorter in malignant than in benign nodule.The rate of rising of intensity signal in the parenchyma around malignant nodule was greater than in benign.
10.With a sensitivity of 98.0%and a specificity of 96.2%,contrast-enhanced ultrasound combining conventional ultrasound is superior to conventional ultrasound.
Conclusions
Contrast-enhanced ultrasound is of great value in diagnosing and differentiating thyroid nodules.Combining conventional ultrasound with contrast-enhanced ultrasound is superior to conventional ultrasound.
PartⅡExpression of CD34,CD105,VEGF,CK19 and Ki67 in thyroid nodules and correlation with Contrast-enhanced Ultrasound findings Purpose
To assess the correlation between the quantitative and qualitative imaging findings on contrast-enhanced ultrasound images and the intensity of CD34,CD105, VEGF,CK19 and Ki67 expression in thyroid nodules.
Material and methods
Sixty-two patients with 62 nodules were evaluated with real-time gray-scale contrast-enhanced ultrasound under a low mechanical index.The microbubble contrast agent was Sono Vue.Of the 62 lesions,30 lesions were thyroid papillary carcinoma,51were goiter,4 were adenoma,1 was Hashimoto's thyroiditis.The paraffined specimens were selected for immunohistochemical staining for CD34, CD105,VEGF,CK19 and Ki67.Comparing the intensity of CD34,CD105,VEGF, CK19 and Ki67 expression between the benign and malignant nodules,correlating them with the characters and patterns of the enhancement of the thyroid nodules.
Results
Higher MVD and VEGF expression was noted in thyroid papillary carcinoma than benign nodules.Angiogenesis is more heterogeneous in malignant than benign nodules,MVD of the margin of the lesions is higher than center.CD105 is superior than CD34 in labeling the tumor newly formed vessel.
Positive correlations have been found in CD34 and unclear enhancing margin, irregular enhancing shape,centreipetal and centrifugal enhancement and reigional enhancement.No correlation was found between CD105 and the findings of the enhancement.Positive correlations have been found in VEGF and unclear enhancing margin,irregular enhancing shape,centreipetal and centrifugal enhancement,a negative correlation has been found between VEGF and rim-like enhancement.
The difference of CD34 between the margin and center is positively correlated with the rising rate of the margin and multi-phase and irregular wash-out.
Negative correlations have been found in VEGF and arrival time,peak time, rising time of nodule and around parenchyma.Positive correlations have been found between VEGF and rising rate,multi-phase and irregular wash-out of nodule.
Positive correlations have been found in CK19 and unclear enhancing margin, irregular enhancing shape,centreipetal and centrifugal enhancement and heterogeneous enhancement.Negtive correlations have been found in CK19 and homogeneous enhancement and rim-like enhancement.
Conclusion
1.MVD and VEGF expression was noted higher in thyroid papillary carcinoma than benign nodules.
2.Contrast-enhanced ultrasound is of great value in assessing angiogenesis in thyroid nodules.There are correlations between MVD、VEGF和CK19 and contrast enhanced ultrasound findings.
1.观察甲状腺结节实时灰阶超声造影的增强形式及时间-强度曲线特征,并与常规超声进行比较。
2.探讨超声造影对甲状腺良恶性结节的鉴别诊断价值。
资料和方法
对95例甲状腺结节患者共104个病灶进行超声造影研究。其中良性结节53个,恶性51个。超声造影剂为SonoVue,技术为低机械指数实时灰阶超声造影成像。
从5方面观察甲状腺结节超声造影增强特征,包括增强边界、增强形态、增强水平、增强方向和增强面积。将超声造影增强模式分为5种类型:无增强、均匀增强、不均匀增强、区域增强和环状增强。脱机分析动态图像在病灶不同部位及周围实质生成时间-强度曲线。总结不同病理类型甲状腺结节的造影增强特点和增强模式,比较甲状腺结节不同部位及良恶性结节之间的时间-强度曲线参数,比较超声造影和常规超声的诊断敏感性、特异性、阳性预测值、阴性预测值。
结果
1.增强边界不清提示恶性的敏感性47%,特异性87%,阳性预测值77%,阴性预测值63%。
2.增强形态不规则提示恶性的敏感性55%,特异性94%,阳性预测值90%,阴性预测值68%。
3.增强面积大于50%提示恶性的敏感性84%,特异性42%,阳性预测值58%,阴性预测值73%。
4.向心或离心性增强提示恶性的敏感性61%,特异性77%,阳性预测值72%,阴性预测值67%。
5.非均匀增强提示恶性的敏感性31%,特异性98%,阳性预测值94%,阴性预测值60%。
6.区域增强提示恶性的敏感性57%,特异性94%,阳性预测值91%,阴性预测值69%。
7.环状增强提示良性的敏感性83%,特异性94%,阳性预测值94%,阴性预测值83%。
8.多向+不规则廓清提示恶性的敏感性62%,特异性94%,阳性预测值94%,阴性预测值79%。
9.恶性结节较良性结节微泡进入强度低、上升时间短,且恶性结节周围实质增强上升速率大于良性结节。
10.超声造影结合灰阶及彩色多普勒诊断甲状腺结节的敏感性98.0%,特异性96.2%,高于常规超声。
结论
超声造影在甲状腺结节诊断和鉴别诊断中具有重要应用价值,超声造影结合灰阶及彩色多普勒的诊断敏感性、特异性均高于后两者单独应用或联合应用。
目的
探讨甲状腺结节实时灰阶超声造影增强形式及时间-强度曲线参数与CD34、CD105、VEGF、CK19和Ki67表达水平的关系。
资料和方法
采用低机械指数实时灰阶谐波超声造影技术,对62例甲状腺病人的62个结节进行超声造影,包括甲状腺乳头状癌30例,结甲27例,腺瘤4例,桥本病1例。术后石蜡标本行CD34、CD105、VEGF、CK19和K167免疫组织化学染色。比较甲状腺良恶性结节CD34、CD105、VEGF、CK19和K167表达水平,分析超声造影增强形式和时间-强度曲线各参数与CD34、CD105、VEGF、CK19和K167表达的关系。
结果
甲状腺乳头状癌结节的MVD和VEGF表达显著高于良性结节。恶性结节新生血管在肿瘤内分布不均衡,癌巢边缘MVD显著高于中心。标记肿瘤新生血管,CD105较CD34特异性更高。
CD34与甲状腺乳头状癌结节增强边界不清、形态不规则、向心+离心增强、区域增强呈正相关。CD105与恶性结节的增强形式之间未发现有意义的相关性。VEGF与结节增强边界不清、增强形态不规则、向心+离心增强正相关,与环状增强负相关。
CD34差值(边缘-中心)与边缘曲线上升速率和多向不规则廓清呈正相关。
VEGF与结节边缘、中心、周围实质的进入时间、达峰时间、上升时间呈负相关。与结节边缘、中心、周围实质的增强速率、多向不规则廓清呈正相关。
CK19与造影的增强方向、增强边界、增强形态、不均匀增强呈正相关;与均匀增强、环状增强呈负相关。
结论
1.甲状腺恶性结节的MVD和VEGF表达显著高于良性结节平均水平。
2.甲状腺实时灰阶超声造影可以反映甲状腺结节血管生成情况,甲状腺结节超声造增强形式及时间-强度曲线参数与MVD、VEGF和CK19之间的多项参数存在相关性。
PartⅠThe Research of Thyroid Nodules by Using Real-time Gray Contrast-enhanced Ultrasound Purpose
1.To observe the enhancement pattern and time-intensity curve of thyroid nodules by using contrast-enhanced ultrasound,and compare with conventional ultrasound.
2.To assess the value of contrast-enhanced ultrasound in differentiating thyroid benign and malignant nodule.
Material and methods
Ninety-five patients scheduled for surgical removal of the nodule were evaluated with real-time gray-scale contrast-enhanced ultrasound under a low mechanical index.The microbubble contrast agent was Sono Vue.Of the 104 lesions,53 lesions were benign,51 were malignant.
The enhancement of the thyroid nodules were characterized from five aspects, including margin,shape,level,orientation and the proportion of enhancement.There are five patterns of enhancement,including non,homogenous,heterogeneous, regional and rim-like enhancement.Analyzing the off-line dynamic images to create the Time-intensity curves in different parts of the thyroid nodules.To analyze the enhancement findings of thyroid nodules with repect to the histological results.To compare time-intensity curves of different parts of the nodule and between benign and malignant nodules.In addition,the sensitivity,specificity,PPV(positive predictive value),NPV(negative predictive value) of the contrast-enhancement ultrasound were calculated and compared with conventional ultrasound.
Results
1.Unclear enhancement-margin was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 47%/87%/77%/63%.
2.Irregular enhancement-shape was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 55%/94%/90%/68%.
3.Enhancement-proportion＞50%was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 84%/42%/58%/73%.
4.Centripetal and Centrifugal enhancement was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 61%/77%/72%/67%.
5.heterogeneous enhancement was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 31%/98%/94%/60%.
6.Region enhancement was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 57%/94%/91%/69%.
7.Rim-like enhancement was suggestive of benign with a sensitivity/specificity/PPV/NPV of 83%/94%/94%/83%.
8.Multiphase and irregular wash-out was suggestive of malignant with a sensitivity/specificity/PPV/NPV of 62%/94%/94%/79%.
9.The baseline intensity signal was lower and the rising time was shorter in malignant than in benign nodule.The rate of rising of intensity signal in the parenchyma around malignant nodule was greater than in benign.
10.With a sensitivity of 98.0%and a specificity of 96.2%,contrast-enhanced ultrasound combining conventional ultrasound is superior to conventional ultrasound.
Conclusions
Contrast-enhanced ultrasound is of great value in diagnosing and differentiating thyroid nodules.Combining conventional ultrasound with contrast-enhanced ultrasound is superior to conventional ultrasound.
PartⅡExpression of CD34,CD105,VEGF,CK19 and Ki67 in thyroid nodules and correlation with Contrast-enhanced Ultrasound findings Purpose
To assess the correlation between the quantitative and qualitative imaging findings on contrast-enhanced ultrasound images and the intensity of CD34,CD105, VEGF,CK19 and Ki67 expression in thyroid nodules.
Material and methods
Sixty-two patients with 62 nodules were evaluated with real-time gray-scale contrast-enhanced ultrasound under a low mechanical index.The microbubble contrast agent was Sono Vue.Of the 62 lesions,30 lesions were thyroid papillary carcinoma,51were goiter,4 were adenoma,1 was Hashimoto's thyroiditis.The paraffined specimens were selected for immunohistochemical staining for CD34, CD105,VEGF,CK19 and Ki67.Comparing the intensity of CD34,CD105,VEGF, CK19 and Ki67 expression between the benign and malignant nodules,correlating them with the characters and patterns of the enhancement of the thyroid nodules.
Results
Higher MVD and VEGF expression was noted in thyroid papillary carcinoma than benign nodules.Angiogenesis is more heterogeneous in malignant than benign nodules,MVD of the margin of the lesions is higher than center.CD105 is superior than CD34 in labeling the tumor newly formed vessel.
Positive correlations have been found in CD34 and unclear enhancing margin, irregular enhancing shape,centreipetal and centrifugal enhancement and reigional enhancement.No correlation was found between CD105 and the findings of the enhancement.Positive correlations have been found in VEGF and unclear enhancing margin,irregular enhancing shape,centreipetal and centrifugal enhancement,a negative correlation has been found between VEGF and rim-like enhancement.
The difference of CD34 between the margin and center is positively correlated with the rising rate of the margin and multi-phase and irregular wash-out.
Negative correlations have been found in VEGF and arrival time,peak time, rising time of nodule and around parenchyma.Positive correlations have been found between VEGF and rising rate,multi-phase and irregular wash-out of nodule.
Positive correlations have been found in CK19 and unclear enhancing margin, irregular enhancing shape,centreipetal and centrifugal enhancement and heterogeneous enhancement.Negtive correlations have been found in CK19 and homogeneous enhancement and rim-like enhancement.
Conclusion
1.MVD and VEGF expression was noted higher in thyroid papillary carcinoma than benign nodules.
2.Contrast-enhanced ultrasound is of great value in assessing angiogenesis in thyroid nodules.There are correlations between MVD、VEGF和CK19 and contrast enhanced ultrasound findings.
引文
1. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at us Socitety of radiologists in ultrasound consensus conference statement. Radiology, 2005,237: 794-800.
2. Khati N, Adamson T, Johnson KS, et al. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q, 2003,19:162-176.
3. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary carcinoma. J Ultrasound Med, 2003, 22:1083-1090.
4. Papini E, Guglielimi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules:predictive value to ultrasound and color-Doppler features. J Clin Endocrinol Metab, 2002, 87:1941-1946.
5. Ezzat S, Sarti DA, Can DR, et al. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med, 1994,154:1838-1840.
6. Rojeski MT, Gharib H. Nodular thyroid disease: evaluation and management. N Engl J Med, 1985,313:428-36.
7. Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence incidence, and regression of thyroid diseases in adolescent and young adults. Am J Med, 1991, 91:363-70.
8. International Agency for Research on Cancer. Accessed at http://www-dep.iarc.fr.
9. National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at http://www.seer.cnacer.gov.
10. Bhatti WA, Baker SR. The thyroid cancer epidemic: Is it the dark side of the CT revolution? European Journal of Radiology, 2006, 60:67-69.
11. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radation:a pooled analysis of severn studies.Radiat Res,1995,141:259-77.
12. Keston Jones M. Management of nodular thyroid disease. Br Med J, 2001, 323:293-4.
13. Walsh RM, Watkinson JC, Franklyn J. The management of the solitary thyroid nodule: a review. Clin Otolaryngol Allied Sci,1999,24:388-97.
14. Giuffrida D, Gharib H. Controversies in the management of cold, hot, and occult thyroid nodules. Am J Med, 1995, 99:642-50.
15. Bennedbaek FN, Hegedus L . Management of the solitary thyrid nodule: Results of a North American survey. J Clin Endocrinol metab, 2000, 85:1941 -1946.
16. Bonnema SJ, Bennedbaek FN, Ladenson PW, et al. Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab, 2002, 87:112-117.
17. Koike E, Noguchi S, Yamashita H, et al. Utrasonogrphic characteristics of thyroid nodules: Prediction of malignancy. Arch Surg ,2001,136:334-337.
18. Okamoto T, Yamashita I , Harasawa A, et al. Test performances of three diagnostic procedures in evaluationg thyroid nodules:physical examination, ultrasonogrphy and dine needle aspiration cytology. Endocr J, 1994,41:243-247.
19. Watters DA, Ahuja At, Evans RM, et al. Role of ultraound in the management of thyroid nodules . Am J Surg, 1992, 164:654-657.
20. Jun Peter, Chow LC, Jeffrey RB, et al.Pictorial essay:The sonographic features of papillary thyroid carcinomas. Ultrasound Q, 2005, 21:39-45.
21. Cosgrove D. Future prospects for SonoVue and CPS.Eur Radiol Supppl, 2004, 14:S116-S124.
22. Mulvagh SL, DeMaria AN, Feinstein SB, et al. Contrast echocardiography: current and future applications. J Am Soc Echocariogr, 2000,13:331-342.
23. Averkiou M, Powers J, Skyba D, et al, Ultrasound Contrast Imaging Research.Ultrasound Q, 2003,19: 27-37.
24. Spiezia S, Farina R, Cerbone G, et al. Analysis of color Doppler signal intensity variation after levovist injection. J Ultrasound Med, 2001, 20:223-231.
25. Bartolotta TV, Midiri M. Runza G, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound:initial results. Eur Radiol, 2006,16:2234-2241.
26. Akslen LA, Livolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol, 2000, 31:439.
27. Huang SM, Lee JC, Wu TJ, et al. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg, 2001,25:302.
28. Cosgrove D.Angiogenesis imagin-ultrasound. The British Journal of Radiology, 2003, 76:S43-S49.
1. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at us:Society of radiologists in ultrasound consensus conference statement. Radiology, 2005,237: 794-800.
2. Papini E, Guglielimi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules:predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab, 2002, 87:1941-1946.
3. Bennedbaek FN, Hegedus L . Management of the solitary thyroid nodule: Results of a North American survey. J Clin Endocrinol metab, 2000, 85:2493-2498.
4. Bonnema SJ, Bennedbaek FN, Ladenson PW, et al. Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab 2002, 87:112-117.
5. Koike E, Noguchi S, Yamashita H, et al. Utrasonographic characteristics of thyroid nodules: Prediction of malignancy. Arch Surg, 2001,136:334-337.
6. Okamoto T, Yamashita I , Harasawa A, et al. Test performances of three diagnostic procedures in evaluating thyroid nodules:physical examination, ultrasonography and fine needle aspiration cytology. Endocr J, 1994, 41:243-247.
7. Fleischer AC, Niermann, KJ, Donnelly EF, et al. Sonographic depiction of microvessel perfusion principles and potential. J Ultrasound Med, 2004, 23:1499-1506.
8. Kim TK, Jang HJ, Wilson SR, et al. Benign liver masses: imaging with microbubble contrast agents. Ultrasoud Q, 2006,22:31-39.
9. Fleischer AC, Donnelly EF, Grippo RJ, et al. Quantification of tumor vascularity with contrast-enhanced sonography: correlation with magnetic resonance imaging and fluorodeoxyglucose autoradiography in implanted tumor. J Ultrasound Med, 2004,23:37-41.
10. Kiessling F, Krix M, Heilmann M, et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast enhanced intermittent power Doppler sonography.Invest Radiol,2003,38:516-524.
11.Krix M,kiessling F,Vosseler S,et al.Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography:quantification of tumor perfusion in small animals.Ultrasound Med Biol,2003,29:1093-1103.
12.Foster FS,Bums PN,Simpson DH,et al.Ultrasound for the visualization and quantification of tumor microcirculation.Cancer Metastasis Rev,2000,19:131-138.
13.Bums PN,Wilson SR.Microbubble contrast for radiological imaging:1.principles.Ultrasound Q,2006,22:5-13.
14.Quaia E.Contrast media in ultrasonogrpahy:Basic principles and clinical applications.Springer-Verlag BerlinHeidelberg,2005.11-13.
15.Lannuccilli JD,Cronan JJ,Monchik JM,et al.Risk for malignancy of thyroid nodules as assessed by sonographic criteria.The need for biopsy.J ultrasound Med.2004,23,1455-1464.
16.Deng CX,Lizzi FL.A review of physical phenomena associated with ultrosonic contrast agents and illustrative clinical applications.Ultrasound Med Biol,2002,28:277-286.
17.Mulvagh SL,DeMaria AN,Feinstein SB,et al.Contrast echocardiography:current and future applications.J Am Soc Echocariogr,2000,13:331-342.
18.Cosgrove D.Future prospects for SonoVue and CPS.Eur Radiol Supppl,2004,14:S116-S124.
19.Broillet A,Puginier J,Ventrone R,et al.Assessment of myocardial perfusion by intermittent harmonic power Doppler using Sono Vue~(TM),a new ultrasound contrast.Invest Radiol,1998,33:209-215.
20.刘复生,刘彤华主编。肿瘤病理学。北京:北京医科大学中国协和医科大学联合出版社,1997,1318-1338,第三十九章,甲状腺、甲状旁腺肿瘤。谭郁彬。
21.Orel SG,Schnalll MD.MR imaging of the breast for detection,diagnosis,and staging of breast cancer. Radiology, 2001,220: 13-30.
22. Brannigan M, Burns P, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics, 2004, 24:921-935.
23. Correas JM, Claudon M, Tranquart FT, et al. The kidney: imaging with microbubble contrast agents. Ultrasound Q, 2006,22:53-66.
24. Mitchell J, Parangi S. Angiogenesis in benigh and malignant thyroid disease. Thyroid, 2005,15:494-510.
25. Braverman LE, Utiger R. Werner & Ingbar's the thyroid: a fundamental and clinical text.—8~(th) ed .2000,488-511.
26. Roasi J, Carcangiu M, Delellis RA.Tumors of the thyroid gland. In: Atlas of tumor pathology. 3~(rd) seires, fascicle 5. Washington, DC: Armed Forces Instituet of Pathology. 1992.
27. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med,2003,22: 1083-1090.
28. Pacella CM, Guglielmi R, Fabbrini R, et al. Papillary carcinoma in small hypoechoic thyroid nodules: predictive value of echo color Doppler evaluation-preliminary results. J Exp Clin Career Res,1998,17:127-128.
29. Holden A. The role of colour and duplex Doppler ultrasound in the assessment of thyroid nodules. Australas Radiol, 1995,39:343-349.
30. 30. SpieziaS, Farina R, Cerbone G et al. Analysisi of color Doppler signal intensity variation after levovist injection: a new approach to the diagnosis of thyroid nodules. J Ultrasound Med, 2001,20,223-231
31. Jun P, Chow LC, Jeffrey R.B. The sonographic features of papillary thyroid carcinomas: Pictorial essay. Ultrasound Q, 2005,21,211-216.
32. Bartolotta TV, Midiri M. Runza G, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound:initial results. Eur Radiol, 2006,16:2234-2241.
33. Propper RA, Skolnick ML, Weinstein BJ, et al. The nonspecificity of the thyroid halo sign. J Clin Ultrasound, 1980, 8:129-132
34. Watters DA, Ahuja At, Evans RM, et al. Role of ultraound in the management of thyroid nodules . Am J Surg, 1992,164:654-657.
35. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med, 2003, 22:1083-1090.
36. Komolafe F. Radiological patterns and significance of thyroid calcification. Clin Radiol, 1981,32:571-575.
37. Lansford CD, Teknos TN. Evaluation of the thyroid nodule. Cancer Control, 2006,13:89-98.
38. McQuone SJ, Eisele DW. Cervical lymph node metastases in well-differrentiated thyroid carcinoma. Proceedings 4 International Conference on Head and Neck Cancer, 1996, 967-971.
39. Wunderbaldinger P, Harisinghani MG, Hahn PF, et al. Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol, 2002,178:693-697.
40. Mazzaferrri EL, Young RL. Papillary thyroid carcinoma: a ten year follow up report of the impact of therapy in 576 patients. Am J Med, 1981, 70:511-518.
41. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer, 1985, 55:805-828
42. Frankenthaler RA, Sellin RV, Cangir A, et al. Lymph node metastases from papillary-follicular thyroid carcinoma in young patients. Am J Surg, 1990,160:341-343.
43. Correas JM, Burns PN, Lai X,et al. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol, 2000, 35:72-79
44. Argalia G, De Bernardis S, Mariani D, et al. Ultrasonographic contrast agent: evaluation of time-intensity curve in the characterization of solitary thyroid nodules. Radio Med (Torino),.2002,103 :407-13
45. Calliada F, Pallavicini D, Pasamonti M, et al. Topical role and future perspectives of sonographic contrast agents in the differential diagnosis of solid thyroid lesions.Rays, 2000 ,25:191-197.
1. Akslen LA, Livolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol, 2000, 31:439-442
2. Huang SM, Lee JC, Wu TJ, et al. Clinical relevance of vasdcular endothelial growth factor for thyroid neoplasms. World J Surg. 2001,25:302-306
3. Lennard CM, Patel A, Wilson J, Reinhardt B et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery, 2001,129:552.
4. Zhang XS , Zhu XF , Gao J S , et al. Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor. Acta Pharmacol Sin, 2001,22: 731-735.
5. Weidner N , Folkman J , Pozza F , et al. Tumor angiogenesis a new significant and independent prognostic factor in early stage breast carcinoma. Nat Cancer Inst,1992,84:1875-1887.
6. Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad exp ression in colorectal carcinomas and p remalignant lesions. Cancer Res, 2000, 60: 18-20.
7. BeeleyMF, Mclaren KM. Cytokeratin 19 and galectin - 3 immunohistochemist ry in the dirrerential diagnosis of solitary thyroid dules. Histopathology, 2002, 41 :236 - 243.
8. Folkman J. What is the evidence that tumors are angiogenesis dependetnt? Journal of the National Cancer Institute, 1990, 82:4-6.
9. L i C , Guo B , Bernabeu C , et al. Angiogenesis in breast cancer : the role of transforming growth factor betaand CD105. M icrosc Res Tech, 2001,52 : 437-449.
10. Schimming R, Marme D, Endoglin (CD105) expression in aquamous cell carcinoma of the oral cavity. Head & Neck, 2002, 24:151-156.
11. Vliet MV, Dijke CF, Wielopolski PA et al. MR Angiography of tumor-related vasculature:from the clinic to the microenvironment. Radiocraphics, 2005, 25:S85-S98.
12. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non - small cell lung cancer: comparison between anti - CD34 antibody and anti - CD105 antibody. Clin Cancer Res, 2001, 7 : 3410-3415.
13. Akagi K, Dceda Y, Sumiyoshi Y, et al. Estimation of angiogenesis with anti -CD105 immnostaing in the process of colorectal cancer development. Surgery, 2002,131 : S109-S113.
14. Wikstrom P, L issbrantLF , Stattin P, et al. Endoglin (CD105 ) is exp ressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 2002,51 :268-275.
15. Fonsatti E , DelVecchio L, Altomonte M, et al. Endoglinn : An accessory component of the TGF - beta 1 -binding receptor - complex with diagnostic, p rognostic, and bioimmunotherapeutic potential in human malignant. J Cell Physiol, 2001,188 : 1-7.
16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86:353-364
17. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nature Medicine, 2003, 713-725.
18. Takahma M, Tsutsumi M, Tsujiuchi T, et al. Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancer. J Olin Oncol, 1998,28:176-181.
19. Yamaoto S,Konishi I, Niandai M, et al. Expression of vascular endothelial growth (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathnology and patient survival, and analgesic of serum VEGF levels. Br J Cancer, 1997, 76: 1221-1227.
20. Santin Ab, Hermonat PL, Ravaggi A, et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Cynae Oncol, 1999, 20:177-181.
21. Rzeszutko M,Rzeszuko W,Dziegiel P. The morphological analysis of vascularure in thyroid tumours: immunoexpression of CD34 antigen. Folia histochemica encytobiologica,2004,42:235-240.
22.庞达,刘锋,薛英威等.乳腺癌组织中CD105mRNA的表达及其临床病理意义.中华肿瘤杂志,2005,27:38-40.
23.Klein M,Picard E,Vignand J M,et al.Vascular endothelial growth factor gene and protein:strong expression in thryoiditis and thyroid carcinoma.J Endocrinl,1999,161:41-49.
24.Katoh R,Miyagi ERI,Kawaoi A,et al.Expression of vascular endothelial growth factor in human thyroid neoplasm.Hum Pathol,1999,30:891-897.
25.Nagy JA,Brown LF,Senger DR,et al.Pathogenesis of tumor stroma generation:a critical role for leaky blood vessels and fibrin deposition.Biochem Biophy Acta,1989,948:305-326.
26.Foster FS,Bums PN,Simpson DS,et al.Ultrasound for the visualization and quantification of tumor microcirculation.Cancer and metastasis reviews,2000,19:131-138.
27.Bums P,Halliwell M,Wells P,et al.Ultrasonic doppler studies of the breast.Ultrasound Med Biol,1982,8:127-143.
28.Taylor KJW,Ramos I,Carter D,et al.Correlation of doppler us tumor signals with neovascular morphologic feature.Radiology,1988,166:57-62.
29.Kedar RP,Cosgrove DO,Smith IE,et al.Breast carcinoma:measurement of tumor response to prinmary medical therapy with color doppler flow imaging.Radiology,1994,190:825-830.
30.Cosgrove D.Angiogenesis imagin-ultrasound.The British Journal of Radiology,2003,76:S43-S49.
31.Folkman J:New perspectives in clinical oncology from angiogenesis research.Eur J Cancer,1996,32A:2534-2539.
32.Becher H,Bums PN.Handbook of contrast echocardiography.Springer,Berlin,(2000).
33.MuthukkaruppanVR and Auerbach R:Angiogenesis in the mouse cornea.Science,1979,205:1416-1418.
34.Broillet A,Puginier J,Ventrone R,et al.Assessment of myocaecial perfusion by intermittent harmonic power Doppler using SonoVue,a new ultrasound contrast agent.Invest Radiol,1998,33:209-215.
35.Wilson SR,Burns PN,Muradali D,et al.Harmonic hepatic US with microbubble contrast agent:initial experience showing improved characterization of hemangioma,hepatocellular carcinoma,and metastasis.Radiology 2000,215:153-161.
36.Burns PN,Wilson SR,Simpson DH.Pulse inversion imaging of liver blood flow:improved method for characterizing focal masses with microbubble contrast.Invest Radiol,2000,35:58-71.
37.Tiemann K,Lohmeier S,Kuntz S,et al.Real-time contrast echo assessment of myocardial perfusion at low emission power:first experimental and clinical results using power pulse inversion imaging.Echocardiography,1999,16:799-809.
38.王家耀,马金龙.甲状腺与甲状旁腺临床病理学.济南:山东科学技术出版社,2000.
39.廖松林.甲状腺常见疾病的 病理诊断及鉴别诊断.临床与实验病理学杂志,2000,16:510-511.
40.方建萍,王雪莉,汤如勇.CK19和PCNA在甲状腺良恶性乳头状增生上皮中的表达.同济大学学报(医学版),2003,24,478-479.
41.Rapheal SL,Mckeown-Eyssen G;Asa SL.High molecular weight cytokeratin and cytokeratin 19 in the diagnosis of thyroid tumor[J].Mod Pathol,1994,7:295-300.
1. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at us Socitety of radiologists in ultrasound consensus conference statement. Radiology, 2005,237: 794-800.
2. Khati N, Adamson T, Johnson KS, et al. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q, 2003,19:162-176.
3. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary carcinoma. J Ultrasound Med, 2003, 22:1083-1090.
4. Papini E, Guglielimi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules:predictive value to ultrasound and color-Doppler features. J Clin Endocrinol Metab, 2002, 87:1941-1946.
5. Ezzat S, Sarti DA, Can DR, et al. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med, 1994,154:1838-1840.
6. Rojeski MT, Gharib H. Nodular thyroid disease: evaluation and management. N Engl J Med, 1985, 313:428-436.
7. Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence incidence, and regression of thyroid diseases in adolescent and young adults. Am J Med, 1991, 91:363-370.
8. International Agency for Research on Cancer. Accessed at http://www-dep.iarc.fr.
9. Sriram U, Patacsil LM. Thyroid nodules. Dis Mon, 2004, 50:486-526.
10. National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at http://www.seer.cnacer.gov.
11. Bhatti WA, Baker SR. The thyroid cancer epidemic: Is it the dark side of the CT revolution? Eur J Radiology, 2006, 60:67-69.
12. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radation:a pooled analysis of severn studies.Radiat Res, 1995,141:259-277.
13. Keston Jones M. Management of nodular thyroid disease. Br Med J, 2001, 323:293-294.
14.Walsh RM,Watkinson JC,Franklyn J.The management of the solitary thyroid nodule:a review.Clin Otolaryngol Allied Sci,1999,24:388-397.
15.Giuffrida D,Gharib H.Controversies in the management of cold,hot,and occult thyroid nodules.Am J Med,1995,99:642-50.
16.Bennedbaek FN,Hegedus L.Management of the solitary thyrid nodule:Results of a North American survey.J Clin Endocrinol metab,2000,85:1941-1946.
17.Bonnema SJ,Bennedbaek FN,Ladenson PW,et al.Management of the nontoxic multinodular goiter:A North American survey.J Clin Endocrinol Metab,2002,87:112-117.
18.Cosgrove D.Future prospects for SonoVue and CPS.Eur Radiol Supppl,2004,14:s116-s124.
19.Mulvagh SL,DeMaria AN,Feinstein SB,et al.Contrast echocardiography:current and future applications.J Am Soc Echocariogr,2000,13:331-342.
20.焦明德,蔡爱露,吴长君,徐辉雄主编。实用三维超声诊断学。北京:军事医学科学出版社,2003,303-304.
21.刘复生,刘彤华主编。肿瘤病理学。北京:北京医科大学中国协和医科大学联合出版社,1997,1318-1338,第三十九章,甲状腺、甲状旁腺肿瘤。谭郁彬。复生,刘彤华主编
22.Risau W,Flammer I.Vasculogenesis.Annu rev cell dev boil,1995,11:73-91.
23.Hobson B,Denekamp J.Proliferation in tumors and normal tissue:continuous labeling studies.Br J Cancer,1984,49:405-443.
24.Carmeliet P,Jain RK.Angiogenesis in cancer and other disease.Nature,2000,407:249-257.
25.Li C,Guo B,Bernabeu C,et al.Angiogenesis in breast cancer:the role of transforming growth factor betaand CD105.M icrosc Res Tech,2001,52:437-449.
26.Folkman J.What is the evidence that tumors are angiogenesis dependetnt?Journal of the National Cancer Institute,1990,82:4-6.
27.Folkman J,Shing Y.Angiogenesis.J of Bio Chem,1992,267:10931-10934.
28.Denekamp J.Angiogenesis,neovascular proliferation and vascular pthophysiology as targets for cancer therapy.Br J Radiol,1993,66:181-196.
29.Fox SB,Gatter KC,Harris AL.Tumor angiogenesis.J of Pathology,1996,179:232-237.
30.邹戈.肿瘤血管生成与抗血管生成研究进展及其抑制因子研究进展.国外医学肿瘤学分册,2003,8,269-271.
31.Shibuya M.Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.Cell St ruct Funct,2001,26:25-35.
32.32.Ferrara N,Henzel WJ.Pituitary follicular cells secrete a novel hepatin-binding growth factor specific for vascular enedothelial cell.B iochem B iophys Res Commun,1989,161:851-858.
33.Hyder SM,Murthy L,Stancel GM.Progestin regulation of vascular endothelial growth factor in human breast cancer.Cancer Res,1998,58,392-395.
34.Ferrara N.Role of vascular endothelial growth factor in regulation of angiogenesis.Kidney Int,1999,56:794-814.
35.Salven P,Lymboussaki A,Heikkia P,et al.Vascular endothelia growth factor VEGF-B and VEGF-C are expressed in human tumors.Am J Patho,1998,153:103-108.
36.Schimming R,Marme D.Endoglin(CD105) expression in aquamous cell carcinoma of the oral cavity.Head & Neck,2002,24:151-156.
37.Vliet MV,Dijke CF,Wielopolski PA et al.MR Angiography of tumor-related vasculature:from the clinic to the microenvironment.Radiocraphics,2005,25:S85-S98.
38.Tanaka F,Otake Y,Yanagihara K,et al.Evaluation of angiogenesis in non - small cell lung cancer:comparison between anti - CD34 antibody and anti - CD105antibody.Clin Cancer Res,2001,7:3410-3415.
39.Akagi K,Ikeda Y,Sumiyoshi Y,et al.Estimation of angiogenesis with anti-CD105immunostaining in the process of colorectal cancer development.Surgery,2002,131:S109-113.
40.Wikstrom P,L issbrantLF,Stattin P,et al.Endoglin(CD105 ) is expressed on immature blood vessels and is a marker for survival in prostate cancer.Prostate,2002,51:268-275.
41.Fonsatti E,DelVecchio L,AltomonteM,et al.Endoglinn:An accessory component of the TGF - beta 1 -binding receptor - complex with diagnostic,prognostic,and bioimmunotherapeutic potential in human malignant.J Cell Physiol,2001,188:1-7.
42.Dhar DK,Kubota H,Kotoh T,et al.Tumor vascularity predicts recurrence in differentiated thyroid carcinoma.Am J Surg,1998,176:442-447.
43.Scarpino S,Stoppacciaro A,Ballerini F,et al.Papillary carcinoma of the thyroid:evidence for a rule for hepatocyte growth factor(HGF) in promoting tumour angiogenesis.J Pathol,2003,199:243-250.
44.叶财盛,林勇杰,王深明等.滤泡状甲状腺肿瘤微血管密度检测及其临床意义的探讨.中华普通外科杂志.2002,8:481-483.
45.Segal K,Shpitzer T,Feinmesser M,et al.Angiogenesis in follicular tumors of the thyroid.J Surg Oncol,1996,63:95-98.
46.薛刚,姚榛祥.甲状腺癌的微血管密度及其临床意义.中华外科杂志,2000,38:636
47.张维东,高血芹,宋守芹,等.层粘连蛋白受体及微血管密度与甲状腺癌转移的关系.肿瘤,2000,20:334-336.
48.Dhar DK,Kubota H,Kotoh T,et al.Tumor vascularity predict reccurrence in differentiated thyroid carcinoma.Am J Surg,1998,176:442-447.
49.Katoh R,Miyagi ERI,Kawaoi A,et al.Expression of vascular endothelial growth factor in human thyroid neoplasm.Hum Pathol,1999,30:891-897.
50.Klein M,Picard E,Vignand J M,et al.Vascular endothelial growth factor gene and protein:strong expression in thryoiditis and thyroid carcinoma.J Endocrinl,1999,161:41-49.
51.冯白秀.彩色多普勒高频超声诊断甲状腺肿块的分析.临床超声医学杂志.2000.2:177-179.
52.于铭,王全华,王建宏,等.二维及彩色多普勒超声在结节性甲状腺肿诊断 中的应用. 中国超声医学杂志. 2000,16:599-601.
53. 李彩娟, 刘春凤. 临床超声医学杂志. 2005, 7: 307-309.
54. Cosgrove D. Angiogenesis imagin-ultrasound. The British Journal of Radiology, 2003,76:S43-S49
55. Burns PN, Powers JE, Fritzsch T. Harmonic imaging: a new imaging and Doppler method for contrast-enhanced ultrasound. Radiology, 1992,185:142.
56. Hope SD, Chin CT, Burns PN. Pulse inversion doppler: a new method for detecting nonlinear echos from microbubble contrast agents. IEEE Trans. UFFC, 46:372-382.
57. Wilson SR, Burns PN, Muradali D, et al. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis.Radiology, 2000, 215:153-161.
58. Heckemann RA, Cosgrove DO, Blomley MJ, et al. Liver lesions:intermittent second-harmonic gray-scale US can increase conspicuity with microbubble contrast material—early experience. Radiology, 2000,216:592-596.
59. Porter TR, Xie F. Transient myocardial contrast following initial exposure to diagnostic ultrasound pressures with minute doses of intravenously injected microbubbles: demonstration and potential mechanisms In: Nanda N, Schlief R, Goldberg B, eds. Advances in Echolmaging Using Contrast Enhancement. 2nd ed. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996.
60. Porter TR, Xie F, Kricsfeld D, et al. Improved myocardial contrast with second harmonic transient ultrasound response imaging in humans using intravenous perfluorocarbon-exposed sonicated dextrose albumin. J Am Coll Cardiol, 1996;27:1497-1501.
61. Blomley M, Albrecht T, Wilson S, et al. Improved detection of metastatic liver lesions using pulse inversion harmonic imaging with Levovist:a multicenter study. Radiology, 1999,213:491-521.
62. Tiemann K, Becher H, K(o|¨)ster J, et al. Quantification of tissue perfusion by means of bubble destruction using harmonic power Doppler imaging. Circulation, 1998,98:1570.
63. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation, 1998, 97:473-483.
64. Averkiou M, Bruce M, Powers J, inventors; ATL Ultrasound, assigned Ultrasonic Diagnostic Imaging With Contrast Agents. USA patent no. 5,833,613. 1998.
65. 张青萍, 周翔, 柳建华. 放射学实践. 2000,15:170-172.
66. Kawauchi A, Hahimoto Y, Kamiya K, et al. Contrast echo imaging on the breast and thyroid cancers. Nippon Rinsho,1998, 56: 1049-1054.
67. Calliada F, Pallavicini D, Pasamonti M, et al. Topical role and future perspectives of sonographic contrast agents in the differential diagnosis of solid thyroid lesions. Rays, 2000, 25:191-197.
68. Spiezia S, Farina R, Cerbone G, et al. Analysis of color Doppler signal intensity variation after levovist injection: a new approach to the diagnosis of thyroid nodules.J Ultrasound Med. 2001,20:223-31.
69. Berni A, Tromba L, Falvo L.et al.Chir Ital. Malignant thyroid nodules: comparison between color Doppler diagnosis and histological examination of surgical samples. 2002, 54:643-647.
70. Argalia G, De Bernardis S, Mariani D, et al. Ultrasonogrphic contrast agent: evaluation of time-intensity curve in the characterization of solitary thyroid nodules.Radio Med (Torino).2002,103:407-413.
71. Bartolotta TV, Midiri M. Runza G, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound:initial results. Eur Radiol.2006;16:2234-2241.
72. Neufield G, Cohen T, Stela G, et al.Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 1999, 13:9- 22.
73. Koike E, Noguchi S, Yamashita H, et al. Utrasonogrphic characteristics of thyroid nodules: Prediction of malignancy. Arch Surg ,2001 ;136:334-337.
74. Okamoto T, Yamashita I , Harasawa A, et al. Test performances of three diagnostic procedures in evaluationg thyroid nodules:physical examination, ultrasonogrphy and dine needle aspiration cytology. Endocr J,1994,41:243-247.
75. Watters DA, Ahuja At, Evans RM, et al. Role of ultraound in the management of thyroid nodules . Am J Surg, 1992,164:654-657.
76. Jun Peter, Chow LC, Jeffrey RB, et al. The sonographic features of papillary thyroid carcinomas pictorial essay. Ultrasound Q, 2005,21:39-45.
2. Khati N, Adamson T, Johnson KS, et al. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q, 2003,19:162-176.
3. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary carcinoma. J Ultrasound Med, 2003, 22:1083-1090.
4. Papini E, Guglielimi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules:predictive value to ultrasound and color-Doppler features. J Clin Endocrinol Metab, 2002, 87:1941-1946.
5. Ezzat S, Sarti DA, Can DR, et al. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med, 1994,154:1838-1840.
6. Rojeski MT, Gharib H. Nodular thyroid disease: evaluation and management. N Engl J Med, 1985,313:428-36.
7. Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence incidence, and regression of thyroid diseases in adolescent and young adults. Am J Med, 1991, 91:363-70.
8. International Agency for Research on Cancer. Accessed at http://www-dep.iarc.fr.
9. National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at http://www.seer.cnacer.gov.
10. Bhatti WA, Baker SR. The thyroid cancer epidemic: Is it the dark side of the CT revolution? European Journal of Radiology, 2006, 60:67-69.
11. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radation:a pooled analysis of severn studies.Radiat Res,1995,141:259-77.
12. Keston Jones M. Management of nodular thyroid disease. Br Med J, 2001, 323:293-4.
13. Walsh RM, Watkinson JC, Franklyn J. The management of the solitary thyroid nodule: a review. Clin Otolaryngol Allied Sci,1999,24:388-97.
14. Giuffrida D, Gharib H. Controversies in the management of cold, hot, and occult thyroid nodules. Am J Med, 1995, 99:642-50.
15. Bennedbaek FN, Hegedus L . Management of the solitary thyrid nodule: Results of a North American survey. J Clin Endocrinol metab, 2000, 85:1941 -1946.
16. Bonnema SJ, Bennedbaek FN, Ladenson PW, et al. Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab, 2002, 87:112-117.
17. Koike E, Noguchi S, Yamashita H, et al. Utrasonogrphic characteristics of thyroid nodules: Prediction of malignancy. Arch Surg ,2001,136:334-337.
18. Okamoto T, Yamashita I , Harasawa A, et al. Test performances of three diagnostic procedures in evaluationg thyroid nodules:physical examination, ultrasonogrphy and dine needle aspiration cytology. Endocr J, 1994,41:243-247.
19. Watters DA, Ahuja At, Evans RM, et al. Role of ultraound in the management of thyroid nodules . Am J Surg, 1992, 164:654-657.
20. Jun Peter, Chow LC, Jeffrey RB, et al.Pictorial essay:The sonographic features of papillary thyroid carcinomas. Ultrasound Q, 2005, 21:39-45.
21. Cosgrove D. Future prospects for SonoVue and CPS.Eur Radiol Supppl, 2004, 14:S116-S124.
22. Mulvagh SL, DeMaria AN, Feinstein SB, et al. Contrast echocardiography: current and future applications. J Am Soc Echocariogr, 2000,13:331-342.
23. Averkiou M, Powers J, Skyba D, et al, Ultrasound Contrast Imaging Research.Ultrasound Q, 2003,19: 27-37.
24. Spiezia S, Farina R, Cerbone G, et al. Analysis of color Doppler signal intensity variation after levovist injection. J Ultrasound Med, 2001, 20:223-231.
25. Bartolotta TV, Midiri M. Runza G, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound:initial results. Eur Radiol, 2006,16:2234-2241.
26. Akslen LA, Livolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol, 2000, 31:439.
27. Huang SM, Lee JC, Wu TJ, et al. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg, 2001,25:302.
28. Cosgrove D.Angiogenesis imagin-ultrasound. The British Journal of Radiology, 2003, 76:S43-S49.
1. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at us:Society of radiologists in ultrasound consensus conference statement. Radiology, 2005,237: 794-800.
2. Papini E, Guglielimi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules:predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab, 2002, 87:1941-1946.
3. Bennedbaek FN, Hegedus L . Management of the solitary thyroid nodule: Results of a North American survey. J Clin Endocrinol metab, 2000, 85:2493-2498.
4. Bonnema SJ, Bennedbaek FN, Ladenson PW, et al. Management of the nontoxic multinodular goiter: A North American survey. J Clin Endocrinol Metab 2002, 87:112-117.
5. Koike E, Noguchi S, Yamashita H, et al. Utrasonographic characteristics of thyroid nodules: Prediction of malignancy. Arch Surg, 2001,136:334-337.
6. Okamoto T, Yamashita I , Harasawa A, et al. Test performances of three diagnostic procedures in evaluating thyroid nodules:physical examination, ultrasonography and fine needle aspiration cytology. Endocr J, 1994, 41:243-247.
7. Fleischer AC, Niermann, KJ, Donnelly EF, et al. Sonographic depiction of microvessel perfusion principles and potential. J Ultrasound Med, 2004, 23:1499-1506.
8. Kim TK, Jang HJ, Wilson SR, et al. Benign liver masses: imaging with microbubble contrast agents. Ultrasoud Q, 2006,22:31-39.
9. Fleischer AC, Donnelly EF, Grippo RJ, et al. Quantification of tumor vascularity with contrast-enhanced sonography: correlation with magnetic resonance imaging and fluorodeoxyglucose autoradiography in implanted tumor. J Ultrasound Med, 2004,23:37-41.
10. Kiessling F, Krix M, Heilmann M, et al. Comparing dynamic parameters of tumor vascularization in nude mice revealed by magnetic resonance imaging and contrast enhanced intermittent power Doppler sonography.Invest Radiol,2003,38:516-524.
11.Krix M,kiessling F,Vosseler S,et al.Comparison of intermittent-bolus contrast imaging with conventional power Doppler sonography:quantification of tumor perfusion in small animals.Ultrasound Med Biol,2003,29:1093-1103.
12.Foster FS,Bums PN,Simpson DH,et al.Ultrasound for the visualization and quantification of tumor microcirculation.Cancer Metastasis Rev,2000,19:131-138.
13.Bums PN,Wilson SR.Microbubble contrast for radiological imaging:1.principles.Ultrasound Q,2006,22:5-13.
14.Quaia E.Contrast media in ultrasonogrpahy:Basic principles and clinical applications.Springer-Verlag BerlinHeidelberg,2005.11-13.
15.Lannuccilli JD,Cronan JJ,Monchik JM,et al.Risk for malignancy of thyroid nodules as assessed by sonographic criteria.The need for biopsy.J ultrasound Med.2004,23,1455-1464.
16.Deng CX,Lizzi FL.A review of physical phenomena associated with ultrosonic contrast agents and illustrative clinical applications.Ultrasound Med Biol,2002,28:277-286.
17.Mulvagh SL,DeMaria AN,Feinstein SB,et al.Contrast echocardiography:current and future applications.J Am Soc Echocariogr,2000,13:331-342.
18.Cosgrove D.Future prospects for SonoVue and CPS.Eur Radiol Supppl,2004,14:S116-S124.
19.Broillet A,Puginier J,Ventrone R,et al.Assessment of myocardial perfusion by intermittent harmonic power Doppler using Sono Vue~(TM),a new ultrasound contrast.Invest Radiol,1998,33:209-215.
20.刘复生,刘彤华主编。肿瘤病理学。北京:北京医科大学中国协和医科大学联合出版社,1997,1318-1338,第三十九章,甲状腺、甲状旁腺肿瘤。谭郁彬。
21.Orel SG,Schnalll MD.MR imaging of the breast for detection,diagnosis,and staging of breast cancer. Radiology, 2001,220: 13-30.
22. Brannigan M, Burns P, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics, 2004, 24:921-935.
23. Correas JM, Claudon M, Tranquart FT, et al. The kidney: imaging with microbubble contrast agents. Ultrasound Q, 2006,22:53-66.
24. Mitchell J, Parangi S. Angiogenesis in benigh and malignant thyroid disease. Thyroid, 2005,15:494-510.
25. Braverman LE, Utiger R. Werner & Ingbar's the thyroid: a fundamental and clinical text.—8~(th) ed .2000,488-511.
26. Roasi J, Carcangiu M, Delellis RA.Tumors of the thyroid gland. In: Atlas of tumor pathology. 3~(rd) seires, fascicle 5. Washington, DC: Armed Forces Instituet of Pathology. 1992.
27. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med,2003,22: 1083-1090.
28. Pacella CM, Guglielmi R, Fabbrini R, et al. Papillary carcinoma in small hypoechoic thyroid nodules: predictive value of echo color Doppler evaluation-preliminary results. J Exp Clin Career Res,1998,17:127-128.
29. Holden A. The role of colour and duplex Doppler ultrasound in the assessment of thyroid nodules. Australas Radiol, 1995,39:343-349.
30. 30. SpieziaS, Farina R, Cerbone G et al. Analysisi of color Doppler signal intensity variation after levovist injection: a new approach to the diagnosis of thyroid nodules. J Ultrasound Med, 2001,20,223-231
31. Jun P, Chow LC, Jeffrey R.B. The sonographic features of papillary thyroid carcinomas: Pictorial essay. Ultrasound Q, 2005,21,211-216.
32. Bartolotta TV, Midiri M. Runza G, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound:initial results. Eur Radiol, 2006,16:2234-2241.
33. Propper RA, Skolnick ML, Weinstein BJ, et al. The nonspecificity of the thyroid halo sign. J Clin Ultrasound, 1980, 8:129-132
34. Watters DA, Ahuja At, Evans RM, et al. Role of ultraound in the management of thyroid nodules . Am J Surg, 1992,164:654-657.
35. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med, 2003, 22:1083-1090.
36. Komolafe F. Radiological patterns and significance of thyroid calcification. Clin Radiol, 1981,32:571-575.
37. Lansford CD, Teknos TN. Evaluation of the thyroid nodule. Cancer Control, 2006,13:89-98.
38. McQuone SJ, Eisele DW. Cervical lymph node metastases in well-differrentiated thyroid carcinoma. Proceedings 4 International Conference on Head and Neck Cancer, 1996, 967-971.
39. Wunderbaldinger P, Harisinghani MG, Hahn PF, et al. Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol, 2002,178:693-697.
40. Mazzaferrri EL, Young RL. Papillary thyroid carcinoma: a ten year follow up report of the impact of therapy in 576 patients. Am J Med, 1981, 70:511-518.
41. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid: a clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer, 1985, 55:805-828
42. Frankenthaler RA, Sellin RV, Cangir A, et al. Lymph node metastases from papillary-follicular thyroid carcinoma in young patients. Am J Surg, 1990,160:341-343.
43. Correas JM, Burns PN, Lai X,et al. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol, 2000, 35:72-79
44. Argalia G, De Bernardis S, Mariani D, et al. Ultrasonographic contrast agent: evaluation of time-intensity curve in the characterization of solitary thyroid nodules. Radio Med (Torino),.2002,103 :407-13
45. Calliada F, Pallavicini D, Pasamonti M, et al. Topical role and future perspectives of sonographic contrast agents in the differential diagnosis of solid thyroid lesions.Rays, 2000 ,25:191-197.
1. Akslen LA, Livolsi VA. Increased angiogenesis in papillary thyroid carcinoma but lack of prognostic importance. Hum Pathol, 2000, 31:439-442
2. Huang SM, Lee JC, Wu TJ, et al. Clinical relevance of vasdcular endothelial growth factor for thyroid neoplasms. World J Surg. 2001,25:302-306
3. Lennard CM, Patel A, Wilson J, Reinhardt B et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery, 2001,129:552.
4. Zhang XS , Zhu XF , Gao J S , et al. Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor. Acta Pharmacol Sin, 2001,22: 731-735.
5. Weidner N , Folkman J , Pozza F , et al. Tumor angiogenesis a new significant and independent prognostic factor in early stage breast carcinoma. Nat Cancer Inst,1992,84:1875-1887.
6. Hao XP, Willis JE, Pretlow TG, et al. Loss of fragile histidine triad exp ression in colorectal carcinomas and p remalignant lesions. Cancer Res, 2000, 60: 18-20.
7. BeeleyMF, Mclaren KM. Cytokeratin 19 and galectin - 3 immunohistochemist ry in the dirrerential diagnosis of solitary thyroid dules. Histopathology, 2002, 41 :236 - 243.
8. Folkman J. What is the evidence that tumors are angiogenesis dependetnt? Journal of the National Cancer Institute, 1990, 82:4-6.
9. L i C , Guo B , Bernabeu C , et al. Angiogenesis in breast cancer : the role of transforming growth factor betaand CD105. M icrosc Res Tech, 2001,52 : 437-449.
10. Schimming R, Marme D, Endoglin (CD105) expression in aquamous cell carcinoma of the oral cavity. Head & Neck, 2002, 24:151-156.
11. Vliet MV, Dijke CF, Wielopolski PA et al. MR Angiography of tumor-related vasculature:from the clinic to the microenvironment. Radiocraphics, 2005, 25:S85-S98.
12. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non - small cell lung cancer: comparison between anti - CD34 antibody and anti - CD105 antibody. Clin Cancer Res, 2001, 7 : 3410-3415.
13. Akagi K, Dceda Y, Sumiyoshi Y, et al. Estimation of angiogenesis with anti -CD105 immnostaing in the process of colorectal cancer development. Surgery, 2002,131 : S109-S113.
14. Wikstrom P, L issbrantLF , Stattin P, et al. Endoglin (CD105 ) is exp ressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 2002,51 :268-275.
15. Fonsatti E , DelVecchio L, Altomonte M, et al. Endoglinn : An accessory component of the TGF - beta 1 -binding receptor - complex with diagnostic, p rognostic, and bioimmunotherapeutic potential in human malignant. J Cell Physiol, 2001,188 : 1-7.
16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86:353-364
17. McDonald DM, Choyke PL. Imaging of angiogenesis: from microscope to clinic. Nature Medicine, 2003, 713-725.
18. Takahma M, Tsutsumi M, Tsujiuchi T, et al. Frequent expression of the vascular endothelial growth factor in human non-small-cell lung cancer. J Olin Oncol, 1998,28:176-181.
19. Yamaoto S,Konishi I, Niandai M, et al. Expression of vascular endothelial growth (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathnology and patient survival, and analgesic of serum VEGF levels. Br J Cancer, 1997, 76: 1221-1227.
20. Santin Ab, Hermonat PL, Ravaggi A, et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Cynae Oncol, 1999, 20:177-181.
21. Rzeszutko M,Rzeszuko W,Dziegiel P. The morphological analysis of vascularure in thyroid tumours: immunoexpression of CD34 antigen. Folia histochemica encytobiologica,2004,42:235-240.
22.庞达,刘锋,薛英威等.乳腺癌组织中CD105mRNA的表达及其临床病理意义.中华肿瘤杂志,2005,27:38-40.
23.Klein M,Picard E,Vignand J M,et al.Vascular endothelial growth factor gene and protein:strong expression in thryoiditis and thyroid carcinoma.J Endocrinl,1999,161:41-49.
24.Katoh R,Miyagi ERI,Kawaoi A,et al.Expression of vascular endothelial growth factor in human thyroid neoplasm.Hum Pathol,1999,30:891-897.
25.Nagy JA,Brown LF,Senger DR,et al.Pathogenesis of tumor stroma generation:a critical role for leaky blood vessels and fibrin deposition.Biochem Biophy Acta,1989,948:305-326.
26.Foster FS,Bums PN,Simpson DS,et al.Ultrasound for the visualization and quantification of tumor microcirculation.Cancer and metastasis reviews,2000,19:131-138.
27.Bums P,Halliwell M,Wells P,et al.Ultrasonic doppler studies of the breast.Ultrasound Med Biol,1982,8:127-143.
28.Taylor KJW,Ramos I,Carter D,et al.Correlation of doppler us tumor signals with neovascular morphologic feature.Radiology,1988,166:57-62.
29.Kedar RP,Cosgrove DO,Smith IE,et al.Breast carcinoma:measurement of tumor response to prinmary medical therapy with color doppler flow imaging.Radiology,1994,190:825-830.
30.Cosgrove D.Angiogenesis imagin-ultrasound.The British Journal of Radiology,2003,76:S43-S49.
31.Folkman J:New perspectives in clinical oncology from angiogenesis research.Eur J Cancer,1996,32A:2534-2539.
32.Becher H,Bums PN.Handbook of contrast echocardiography.Springer,Berlin,(2000).
33.MuthukkaruppanVR and Auerbach R:Angiogenesis in the mouse cornea.Science,1979,205:1416-1418.
34.Broillet A,Puginier J,Ventrone R,et al.Assessment of myocaecial perfusion by intermittent harmonic power Doppler using SonoVue,a new ultrasound contrast agent.Invest Radiol,1998,33:209-215.
35.Wilson SR,Burns PN,Muradali D,et al.Harmonic hepatic US with microbubble contrast agent:initial experience showing improved characterization of hemangioma,hepatocellular carcinoma,and metastasis.Radiology 2000,215:153-161.
36.Burns PN,Wilson SR,Simpson DH.Pulse inversion imaging of liver blood flow:improved method for characterizing focal masses with microbubble contrast.Invest Radiol,2000,35:58-71.
37.Tiemann K,Lohmeier S,Kuntz S,et al.Real-time contrast echo assessment of myocardial perfusion at low emission power:first experimental and clinical results using power pulse inversion imaging.Echocardiography,1999,16:799-809.
38.王家耀,马金龙.甲状腺与甲状旁腺临床病理学.济南:山东科学技术出版社,2000.
39.廖松林.甲状腺常见疾病的 病理诊断及鉴别诊断.临床与实验病理学杂志,2000,16:510-511.
40.方建萍,王雪莉,汤如勇.CK19和PCNA在甲状腺良恶性乳头状增生上皮中的表达.同济大学学报(医学版),2003,24,478-479.
41.Rapheal SL,Mckeown-Eyssen G;Asa SL.High molecular weight cytokeratin and cytokeratin 19 in the diagnosis of thyroid tumor[J].Mod Pathol,1994,7:295-300.
1. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at us Socitety of radiologists in ultrasound consensus conference statement. Radiology, 2005,237: 794-800.
2. Khati N, Adamson T, Johnson KS, et al. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q, 2003,19:162-176.
3. Chan BK, Desser TS, McDougall IR, et al. Common and uncommon sonographic features of papillary carcinoma. J Ultrasound Med, 2003, 22:1083-1090.
4. Papini E, Guglielimi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules:predictive value to ultrasound and color-Doppler features. J Clin Endocrinol Metab, 2002, 87:1941-1946.
5. Ezzat S, Sarti DA, Can DR, et al. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med, 1994,154:1838-1840.
6. Rojeski MT, Gharib H. Nodular thyroid disease: evaluation and management. N Engl J Med, 1985, 313:428-436.
7. Rallison ML, Dobyns BM, Meikle AW, et al. Natural history of thyroid abnormalities: prevalence incidence, and regression of thyroid diseases in adolescent and young adults. Am J Med, 1991, 91:363-370.
8. International Agency for Research on Cancer. Accessed at http://www-dep.iarc.fr.
9. Sriram U, Patacsil LM. Thyroid nodules. Dis Mon, 2004, 50:486-526.
10. National Cancer Institute. Surveillance, Epidemiology and End Results Program. Available at http://www.seer.cnacer.gov.
11. Bhatti WA, Baker SR. The thyroid cancer epidemic: Is it the dark side of the CT revolution? Eur J Radiology, 2006, 60:67-69.
12. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radation:a pooled analysis of severn studies.Radiat Res, 1995,141:259-277.
13. Keston Jones M. Management of nodular thyroid disease. Br Med J, 2001, 323:293-294.
14.Walsh RM,Watkinson JC,Franklyn J.The management of the solitary thyroid nodule:a review.Clin Otolaryngol Allied Sci,1999,24:388-397.
15.Giuffrida D,Gharib H.Controversies in the management of cold,hot,and occult thyroid nodules.Am J Med,1995,99:642-50.
16.Bennedbaek FN,Hegedus L.Management of the solitary thyrid nodule:Results of a North American survey.J Clin Endocrinol metab,2000,85:1941-1946.
17.Bonnema SJ,Bennedbaek FN,Ladenson PW,et al.Management of the nontoxic multinodular goiter:A North American survey.J Clin Endocrinol Metab,2002,87:112-117.
18.Cosgrove D.Future prospects for SonoVue and CPS.Eur Radiol Supppl,2004,14:s116-s124.
19.Mulvagh SL,DeMaria AN,Feinstein SB,et al.Contrast echocardiography:current and future applications.J Am Soc Echocariogr,2000,13:331-342.
20.焦明德,蔡爱露,吴长君,徐辉雄主编。实用三维超声诊断学。北京:军事医学科学出版社,2003,303-304.
21.刘复生,刘彤华主编。肿瘤病理学。北京:北京医科大学中国协和医科大学联合出版社,1997,1318-1338,第三十九章,甲状腺、甲状旁腺肿瘤。谭郁彬。复生,刘彤华主编
22.Risau W,Flammer I.Vasculogenesis.Annu rev cell dev boil,1995,11:73-91.
23.Hobson B,Denekamp J.Proliferation in tumors and normal tissue:continuous labeling studies.Br J Cancer,1984,49:405-443.
24.Carmeliet P,Jain RK.Angiogenesis in cancer and other disease.Nature,2000,407:249-257.
25.Li C,Guo B,Bernabeu C,et al.Angiogenesis in breast cancer:the role of transforming growth factor betaand CD105.M icrosc Res Tech,2001,52:437-449.
26.Folkman J.What is the evidence that tumors are angiogenesis dependetnt?Journal of the National Cancer Institute,1990,82:4-6.
27.Folkman J,Shing Y.Angiogenesis.J of Bio Chem,1992,267:10931-10934.
28.Denekamp J.Angiogenesis,neovascular proliferation and vascular pthophysiology as targets for cancer therapy.Br J Radiol,1993,66:181-196.
29.Fox SB,Gatter KC,Harris AL.Tumor angiogenesis.J of Pathology,1996,179:232-237.
30.邹戈.肿瘤血管生成与抗血管生成研究进展及其抑制因子研究进展.国外医学肿瘤学分册,2003,8,269-271.
31.Shibuya M.Structure and function of VEGF/VEGF-receptor system involved in angiogenesis.Cell St ruct Funct,2001,26:25-35.
32.32.Ferrara N,Henzel WJ.Pituitary follicular cells secrete a novel hepatin-binding growth factor specific for vascular enedothelial cell.B iochem B iophys Res Commun,1989,161:851-858.
33.Hyder SM,Murthy L,Stancel GM.Progestin regulation of vascular endothelial growth factor in human breast cancer.Cancer Res,1998,58,392-395.
34.Ferrara N.Role of vascular endothelial growth factor in regulation of angiogenesis.Kidney Int,1999,56:794-814.
35.Salven P,Lymboussaki A,Heikkia P,et al.Vascular endothelia growth factor VEGF-B and VEGF-C are expressed in human tumors.Am J Patho,1998,153:103-108.
36.Schimming R,Marme D.Endoglin(CD105) expression in aquamous cell carcinoma of the oral cavity.Head & Neck,2002,24:151-156.
37.Vliet MV,Dijke CF,Wielopolski PA et al.MR Angiography of tumor-related vasculature:from the clinic to the microenvironment.Radiocraphics,2005,25:S85-S98.
38.Tanaka F,Otake Y,Yanagihara K,et al.Evaluation of angiogenesis in non - small cell lung cancer:comparison between anti - CD34 antibody and anti - CD105antibody.Clin Cancer Res,2001,7:3410-3415.
39.Akagi K,Ikeda Y,Sumiyoshi Y,et al.Estimation of angiogenesis with anti-CD105immunostaining in the process of colorectal cancer development.Surgery,2002,131:S109-113.
40.Wikstrom P,L issbrantLF,Stattin P,et al.Endoglin(CD105 ) is expressed on immature blood vessels and is a marker for survival in prostate cancer.Prostate,2002,51:268-275.
41.Fonsatti E,DelVecchio L,AltomonteM,et al.Endoglinn:An accessory component of the TGF - beta 1 -binding receptor - complex with diagnostic,prognostic,and bioimmunotherapeutic potential in human malignant.J Cell Physiol,2001,188:1-7.
42.Dhar DK,Kubota H,Kotoh T,et al.Tumor vascularity predicts recurrence in differentiated thyroid carcinoma.Am J Surg,1998,176:442-447.
43.Scarpino S,Stoppacciaro A,Ballerini F,et al.Papillary carcinoma of the thyroid:evidence for a rule for hepatocyte growth factor(HGF) in promoting tumour angiogenesis.J Pathol,2003,199:243-250.
44.叶财盛,林勇杰,王深明等.滤泡状甲状腺肿瘤微血管密度检测及其临床意义的探讨.中华普通外科杂志.2002,8:481-483.
45.Segal K,Shpitzer T,Feinmesser M,et al.Angiogenesis in follicular tumors of the thyroid.J Surg Oncol,1996,63:95-98.
46.薛刚,姚榛祥.甲状腺癌的微血管密度及其临床意义.中华外科杂志,2000,38:636
47.张维东,高血芹,宋守芹,等.层粘连蛋白受体及微血管密度与甲状腺癌转移的关系.肿瘤,2000,20:334-336.
48.Dhar DK,Kubota H,Kotoh T,et al.Tumor vascularity predict reccurrence in differentiated thyroid carcinoma.Am J Surg,1998,176:442-447.
49.Katoh R,Miyagi ERI,Kawaoi A,et al.Expression of vascular endothelial growth factor in human thyroid neoplasm.Hum Pathol,1999,30:891-897.
50.Klein M,Picard E,Vignand J M,et al.Vascular endothelial growth factor gene and protein:strong expression in thryoiditis and thyroid carcinoma.J Endocrinl,1999,161:41-49.
51.冯白秀.彩色多普勒高频超声诊断甲状腺肿块的分析.临床超声医学杂志.2000.2:177-179.
52.于铭,王全华,王建宏,等.二维及彩色多普勒超声在结节性甲状腺肿诊断 中的应用. 中国超声医学杂志. 2000,16:599-601.
53. 李彩娟, 刘春凤. 临床超声医学杂志. 2005, 7: 307-309.
54. Cosgrove D. Angiogenesis imagin-ultrasound. The British Journal of Radiology, 2003,76:S43-S49
55. Burns PN, Powers JE, Fritzsch T. Harmonic imaging: a new imaging and Doppler method for contrast-enhanced ultrasound. Radiology, 1992,185:142.
56. Hope SD, Chin CT, Burns PN. Pulse inversion doppler: a new method for detecting nonlinear echos from microbubble contrast agents. IEEE Trans. UFFC, 46:372-382.
57. Wilson SR, Burns PN, Muradali D, et al. Harmonic hepatic US with microbubble contrast agent: initial experience showing improved characterization of hemangioma, hepatocellular carcinoma, and metastasis.Radiology, 2000, 215:153-161.
58. Heckemann RA, Cosgrove DO, Blomley MJ, et al. Liver lesions:intermittent second-harmonic gray-scale US can increase conspicuity with microbubble contrast material—early experience. Radiology, 2000,216:592-596.
59. Porter TR, Xie F. Transient myocardial contrast following initial exposure to diagnostic ultrasound pressures with minute doses of intravenously injected microbubbles: demonstration and potential mechanisms In: Nanda N, Schlief R, Goldberg B, eds. Advances in Echolmaging Using Contrast Enhancement. 2nd ed. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996.
60. Porter TR, Xie F, Kricsfeld D, et al. Improved myocardial contrast with second harmonic transient ultrasound response imaging in humans using intravenous perfluorocarbon-exposed sonicated dextrose albumin. J Am Coll Cardiol, 1996;27:1497-1501.
61. Blomley M, Albrecht T, Wilson S, et al. Improved detection of metastatic liver lesions using pulse inversion harmonic imaging with Levovist:a multicenter study. Radiology, 1999,213:491-521.
62. Tiemann K, Becher H, K(o|¨)ster J, et al. Quantification of tissue perfusion by means of bubble destruction using harmonic power Doppler imaging. Circulation, 1998,98:1570.
63. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation, 1998, 97:473-483.
64. Averkiou M, Bruce M, Powers J, inventors; ATL Ultrasound, assigned Ultrasonic Diagnostic Imaging With Contrast Agents. USA patent no. 5,833,613. 1998.
65. 张青萍, 周翔, 柳建华. 放射学实践. 2000,15:170-172.
66. Kawauchi A, Hahimoto Y, Kamiya K, et al. Contrast echo imaging on the breast and thyroid cancers. Nippon Rinsho,1998, 56: 1049-1054.
67. Calliada F, Pallavicini D, Pasamonti M, et al. Topical role and future perspectives of sonographic contrast agents in the differential diagnosis of solid thyroid lesions. Rays, 2000, 25:191-197.
68. Spiezia S, Farina R, Cerbone G, et al. Analysis of color Doppler signal intensity variation after levovist injection: a new approach to the diagnosis of thyroid nodules.J Ultrasound Med. 2001,20:223-31.
69. Berni A, Tromba L, Falvo L.et al.Chir Ital. Malignant thyroid nodules: comparison between color Doppler diagnosis and histological examination of surgical samples. 2002, 54:643-647.
70. Argalia G, De Bernardis S, Mariani D, et al. Ultrasonogrphic contrast agent: evaluation of time-intensity curve in the characterization of solitary thyroid nodules.Radio Med (Torino).2002,103:407-413.
71. Bartolotta TV, Midiri M. Runza G, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound:initial results. Eur Radiol.2006;16:2234-2241.
72. Neufield G, Cohen T, Stela G, et al.Vascular endothelial growth factor (VEGF) and its receptors. FASEB J, 1999, 13:9- 22.
73. Koike E, Noguchi S, Yamashita H, et al. Utrasonogrphic characteristics of thyroid nodules: Prediction of malignancy. Arch Surg ,2001 ;136:334-337.
74. Okamoto T, Yamashita I , Harasawa A, et al. Test performances of three diagnostic procedures in evaluationg thyroid nodules:physical examination, ultrasonogrphy and dine needle aspiration cytology. Endocr J,1994,41:243-247.
75. Watters DA, Ahuja At, Evans RM, et al. Role of ultraound in the management of thyroid nodules . Am J Surg, 1992,164:654-657.
76. Jun Peter, Chow LC, Jeffrey RB, et al. The sonographic features of papillary thyroid carcinomas pictorial essay. Ultrasound Q, 2005,21:39-45.